Compare SPDR Gold Trust (GLD) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SPDR Gold Trust vs GSK plc — how do they compare? SPDR Gold Trust trades at $384.26 (market cap $139.66B), while GSK plc trades at $46.65 (market cap $91.88B). The key difference: SPDR Gold Trust is the larger of the two by market cap, and GSK plc pays a 3.9% dividend while SPDR Gold Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold SPDR Gold Trust for 74 Days and GSK plc for 93 Days on average.
| GLD | GSK | |
|---|---|---|
Market Cap | $139.66B | $91.88B |
Volume | 9,544,773 | 7,730,529 |
52-Week High | $495.90 | $61.18 |
52-Week Low | $362.32 | $43.24 |
Typical Hold Time | 74 Days | 93 Days |
Sector | — | Health |
Enterprise Value | — | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLD, the SPDR Gold Trust ETF, is trading at $384.45 with a 2.28% daily gain, though technical indicators signal bearish momentum with 17 sell signals versus 2 buy signals. The ETF faces pressure from rising Treasury yields and a strong U.S. dollar, as highlighted in recent financial news. Key support levels are at $373-$377, while resistance sits at $380-$384. Recent market sentiment remains cautious amid Federal Reserve policy uncertainty and inflation concerns.
The outlook for GLD is mixed, with near-term headwinds from monetary policy and currency strength potentially limiting upside. However, gold's role as a hedge against inflation and global debt concerns offers long-term diversification benefits. Risks include further rate hikes and dollar appreciation, but tactical buying opportunities may emerge if support levels hold.
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
